TABLE 3.
Adherence and compliance
| Factor | Virtual visits (n = 35) | In‐person encounters (n = 35) | p value | ||
|---|---|---|---|---|---|
| n | Statistics | n | Statistics | ||
| Medication compliance | 30 | 24 | 0.58 a | ||
| Full dose | 24 (80.0) | 18 (75.0) | |||
| Not full dose (medical reasons) | 4 (13.3) | 2 (8.3) | |||
| Not full dose (nonadherence) | 2 (6.7) | 4 (16.7) | |||
| Medication tolerance: 4 levels | 28 | 20 | 0.84 a | ||
| Full dose: no side effects | 17 (60.7) | 11 (55.0) | |||
| Full dose: side effects | 7 (25.0) | 7 (35.0) | |||
| Decreased dose: side effects | 2 (7.1) | 1 (5.0) | |||
| Discontinued dose: side effects | 2 (7.1) | 1 (5.0) | |||
| Full visit compliance, n (%) | 35 | 29 (82.9) | 35 | 22 (62.9) | 0.060 b |
| Number of follow‐up visits made, n (%) | 35 | 35 | 0.053 a | ||
| 0 | 1 (2.9) | 4 (11.4) | |||
| 1 | 2 (5.7) | 5 (14.3) | |||
| 2 | 3 (8.6) | 4 (11.4) | |||
| 3 | 29 (82.9) | 22 (62.9) | |||
Note: Statistics presented as n (column %).
a
Wilcoxon rank sum test.
b
Pearson χ2 test.